VIP (Vasoactive Intestinal Peptide)
Endogenous 28-amino-acid neuropeptide. Modulates immune function and inflammation. Used in CIRS (chronic inflammatory response syndrome) protocols and biotoxin exposure recovery, popularized by Dr. Ritchie Shoemaker.
VIP (Vasoactive Intestinal Peptide): Endogenous 28-amino-acid neuropeptide. Modulates immune function and inflammation. Used in CIRS (chronic inflammatory response syndrome) protocols and biotoxin exposure recovery, popularized by Dr. Ritchie Shoemaker. VIP is a 28-amino-acid neuropeptide your body already makes.
VIP is a 28-amino-acid neuropeptide your body already makes. Modulates inflammation and immune function. The well-known use is in Dr. Shoemaker's CIRS protocol for mold/biotoxin illness recovery, used intranasally, multi-month courses, only after upstream prep work.
Endogenous neuropeptide used clinically in CIRS protocols. Federations don't typically address it.
Not FDA approved as a drug. Used in compounded form in CIRS clinical protocols (Shoemaker).
Vasoactive intestinal peptide is in FDA's Category 1, meaning FDA is still evaluating it and has said it does not intend to act against compounding that meets its interim policy's conditions. That is an enforcement posture, not a place on the 503A list.
Yes by some functional-medicine and CIRS-literate providers, via compounding pharmacies.
Who it's for
- →Users with CIRS or mold-illness contexts under medical guidance
- →Chronic inflammatory conditions
- →Post-biotoxin-exposure recovery (well-defined Shoemaker protocol)
What to expect
- Week 1
Some users notice neurological symptom shift early.
- Week 4
Cumulative inflammation markers decline in CIRS context.
- Week 8
Long courses are the norm in CIRS, months to years.
Looking at VIP (Vasoactive Intestinal Peptide)? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for VIP (Vasoactive Intestinal Peptide).
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Endogenous 28-amino-acid neuropeptide. Binds VPAC1 and VPAC2 receptors expressed on immune cells, modulating both Th1/Th2 balance and inflammation. Used clinically (off-label US, on-label some EU contexts) for chronic inflammatory conditions.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Hypotension or unstable cardiovascular status
- ⚠Pregnancy / nursing
- ⚠CIRS protocol specifically requires baseline biotoxin clearance first
Bloodwork to monitor
- • MMP-9, C4a, TGF-β1 in CIRS context (Shoemaker panel)
Common mistakes
- • Running VIP for CIRS without doing the upstream Shoemaker prep first
- • Stopping too early (CIRS courses run months)
- • Treating it as a general anti-inflammatory rather than a specific protocol piece
What it actually is
VIP, vasoactive intestinal peptide, is a 28-amino-acid signalling molecule your body makes throughout the gut, nervous system and immune tissue. It is a real and heavily studied hormone — over 14,000 papers and 91 randomised trials — but nearly all of that is basic physiology and clinical research in specific diseases. The use it is best known for in this space, intranasal dosing in chronic inflammatory response syndrome, is a protocol from one clinician rather than a trial finding.
VIP acts on two receptors, VPAC1 and VPAC2, found on immune cells, blood vessels, airway and gut. It relaxes smooth muscle, dilates blood vessels, and shifts immune responses toward a less inflammatory pattern. That anti-inflammatory action is why it attracted interest for autoimmune and inflammatory conditions. Its half-life is about two minutes, which is the central practical problem: getting a meaningful, sustained amount to the right tissue is genuinely hard, and it is why intranasal dosing is used rather than injection.
Forms, and which is which
The route used in the Shoemaker CIRS protocol, dosed several times daily. Nasal delivery is chosen for proximity to the brain and to avoid the near-instant clearance of systemic dosing.
Verdict: The common route, from a clinical protocol rather than a trial.
Studied for pulmonary hypertension and asthma, where local airway delivery makes mechanistic sense.
Verdict: A legitimate research direction in specific disease.
The two-minute half-life makes sustained systemic exposure impractical, and the vasodilation means blood pressure drops are the limiting effect.
Verdict: Fights the pharmacokinetics and risks hypotension.
Not absorbed intact from the gut.
Verdict: Not plausible as described.
What it is claimed to do, graded
Extensively established physiology, across a very large basic-science literature.
Studied with some encouraging results in small trials. Not established.
This is the use most readers arrive for. CIRS itself is not a diagnosis with broad acceptance in mainstream medicine, and the intranasal VIP protocol comes from one clinician's practice rather than a controlled trial.
An active research direction with a 2022 review behind it. Early.
Not studied at those doses or that duration. Vasodilation and blood pressure effects are the predictable concern.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • A real endogenous hormone with an enormous, legitimate scientific literature
- • The anti-inflammatory mechanism is well established rather than speculative
- • Intranasal dosing is a sensible response to a two-minute half-life
- • Generally well tolerated at the doses used
- • The vast literature is basic physiology, and it is routinely presented as evidence for the CIRS protocol
- • The main use it is sold for rests on one clinician's protocol, not a trial
- • Two-minute half-life makes any systemic dosing strategy questionable
- • Vasodilator effects mean hypotension is a real concern, especially at higher doses
- • Compounded supply, so quality varies
When to stop
- • Lightheadedness, faintness, or a measured drop in blood pressure
- • Flushing that does not settle
- • Headache after dosing
- • No change in the marker or symptom you started it for after a full course
Interactions
VIP is a vasodilator. Additive blood pressure lowering is the predictable interaction.
Compounding vasodilation. Blood pressure can drop further than intended.
Overlapping immune-dampening effects, unstudied together.
Additive vasodilation and hypotension.
Volume depletion plus vasodilation makes a blood pressure drop more likely.
Is this for you?
- • People working through a CIRS protocol with a clinician, understanding it is a practice protocol rather than a trial-backed treatment
- • Anyone interested in the underlying immune physiology
- • You have low blood pressure or unstable cardiovascular status
- • You are pregnant or nursing
- • You take multiple blood-pressure-lowering drugs
- • You are reading the 14,000-paper count as evidence for the protocol — it is not
The one number
Sources for the claims above
- Therapeutic potential of VIP and the VPAC2 receptor in type 2 diabetes
- Hormone overview
- Cardiac actions of vasoactive intestinal peptide
Drug & supplement interactions
- ⚠Vasodilators: additive hypotensive effect
- ⚠Shoemaker CIRS protocol: requires upstream binders and biofilm clearance first, VIP is the last step, not the first
New to VIP (Vasoactive Intestinal Peptide)? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about VIP (Vasoactive Intestinal Peptide) or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is VIP (Vasoactive Intestinal Peptide)?+
Is VIP (Vasoactive Intestinal Peptide) FDA approved?+
Is VIP (Vasoactive Intestinal Peptide) legal?+
Is VIP (Vasoactive Intestinal Peptide) banned by WADA?+
Are you still natty after taking VIP (Vasoactive Intestinal Peptide)?+
Do doctors prescribe VIP (Vasoactive Intestinal Peptide)?+
What's the typical dose of VIP (Vasoactive Intestinal Peptide)?+
What are the side effects of VIP (Vasoactive Intestinal Peptide)?+
How long until VIP (Vasoactive Intestinal Peptide) starts working?+
What can you stack with VIP (Vasoactive Intestinal Peptide)?+
Where do people get VIP (Vasoactive Intestinal Peptide)?+
Common questions about VIP (Vasoactive Intestinal Peptide)
Tracked alongside VIP (Vasoactive Intestinal Peptide)
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Immune
Immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery.
A germ-fighter your immune system already makes on its own. It's a cathelicidin-derived antimicrobial peptide used for chronic infections and biofilm-associated issues.
Calms inflammation in the gut and skin. A tripeptide fragment of alpha-MSH used for gut conditions and skin inflammation.
Used to rebuild a weakened immune system, mainly in older or post-illness patients. A polypeptide complex extracted from calf thymus and distinct from Thymosin Alpha-1, used in Russian and Eastern European clinical practice for immune restoration in elderly patients and post-illness recovery.